Telo Genomics Presents at ASH 2020 The Results of Hodgkin’s Lymphoma Clinical Study

TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has presented the results of its Hodgkin’s lymphoma (HL) clinical study at ASH 2020.

Go here to read the rest:
Telo Genomics Presents at ASH 2020 The Results of Hodgkin’s Lymphoma Clinical Study

Related Post